UCHL1 and hereditary spastic paraplegia: From a clinical perspective, UCHL1 might be considered for exploratory assessment in HSP as a complementary biomarker in HSP to detect or confirm active neurodegeneration, stratify patients based on disease severity, or monitor therapeutic interventions.